CellProthera has selected CELLforCURE by SEQENS as its CDMO partner for Phase 3 manufacturing of ProtheraCytes, an autologous expanded CD34+ stem cell therapy for severe heart attack patients.
CellProthera has begun the PERFECT study, a 10-year observational follow-up to assess ProtheraCytes' long-term safety and efficacy after acute myocardial infarction.
CellProthera has secured FDA alignment on the design for a pivotal Phase III trial of ProtheraCytes, a cell therapy for acute myocardial infarction (AMI).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.